PrEP initiation, persistence, and adherence during pregnancy through the postpartum period: a prospective analysis in Kenya
Participants were offered PrEP during their 2nd trimester and followed through 9-months postpartum. At the end of the study, 58% of PrEP initiators self-reported persistence of use, and 50% of randomly selected DBS had quanitfiable TFV-DP. Having quantifiable TFV-DP was twice as likely during pregnancy than postpartum, and having a partner known to be living with HIV was the strongest predictor of PrEP initiation, persistence, and quantifiable TFV-DP.
Resource Details
- Study Type
- Observational study
- Year
- 2023
- Population
- HIV-uninfected women, Pregnant Women
- Author
- Pintye J, Kinuthia J, Abuna F, Anderson PL, Dettinger JC, Gomez L, Haberer JE, Marwa MM, Ngumbau N, Omondi P, Odhiambo B, Stern J, Watoyi S, Baeten JM, John-Stewart G.
More Publications & Resources
Providing PrEP to Pregnant and Breastfeeding Women
Clinical Practice Guidelines for Providing PrEP for Pregnant and Breastfeeding Populations
Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis
PrEP and PEP Guidelines-Zambia
PrEP Lenacapavir Implementation Guidelines
Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics
Lenacapavir Provider Tools and Job Aids
PrEP Drug Interactions
Zambia PrEP Training Materials for Clinicians and Community Mobilisers
No results found.